Business
CollPlant Biotechnologies to Present on the Use of Collagen BioInk as a Platform for 3D Bioprinting of Tissues and Organs at the Biomaterials For 3D Printing Webinar
REHOVOT, Israel, Aug. 16, 2021 /PRNewswire/ - CollPlant (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and
About this update from Collplant Biotechnologies Ltd.
[{"type":"text","content":"\n REHOVOT, Israel, Aug. 16, 2021 /PRNewswire/ - CollPlant (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced that Dr. Nadav Orr, Vice President of R&D, will present on August 19, 2021, an overview on the use of collagen Bionks for 3D Bioprinting, during the Biomaterials For 3D Printing webinar by 3DHEALS LLC. The presentation is titled \"Collagen BioInk Platform for 3D Bioprinting of Tissues and Organs.\"\n\n \n \n \n \n \n \n\n \n\"We are delighted to make a presentation on our plant-derived, recombinant human collagen-based Bioinks at the Biomaterials For 3D Printing virtual event by 3DHEALS LLC,\" said Dr. Nadav Orr, Vice President of R&D, CollPlant. \"The event will include stakeholders from academia and industry, who will provide a comprehensive view on the future direction of material science technology for healthcare 3D printing.\" \nThe event will be held virtually on August 19, 2021 on 8:00 a.m. to 9:30 a.m. EDT.\nRegistration link: click here \nAbout CollPlant\nCollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine. \nCollPlant recently entered a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market. Later in 2021, CollPlant entered a strategic co-development agreement with 3D Systems for a 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures in combination with an implant. \nFor more information, visit http://www.collplant.com.\nSafe Harbor Statements\nThis press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant's objectives plans and strategies, as well as statements, other than historical facts, that address activities, events or development...